SCHEMBL5401256

SCHEMBL5401256

NC(=S)Cc1nc2ccccc2s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.67
UBE2T Q9NPD8 1/20 0.61
ASIC3 Q9UHC3 1/20 0.61
ALDH1A1 P00352 3/20 0.57
GAA P10253 2/20 0.57
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
HPGD P15428 3/20 0.55
LMNA P02545 1/20 0.54
KDM4E B2RXH2 2/20 0.51
SMN1; SMN2 Q16637 6/20 0.49
RAB9A P51151 5/20 0.49
NPC1 O15118 4/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
TP53 P04637 1/20 0.49
TSHR P16473 1/20 0.49
CASP1 P29466 1/20 0.49
HTT P42858 1/20 0.49
CYP1A2 P05177 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29911182 0.84 MAPT (0.59) MAPTUBE2TASIC3ALDH1A1GAA
SCHEMBL1248386 0.84 MAPT (0.59) MAPTUBE2TASIC3ALDH1A1GAA
SCHEMBL77032 0.83 KMT2A (0.68) MAPTUBE2TASIC3ALDH1A1GAA
SCHEMBL11266911 0.83 MAPT (0.67) MAPTUBE2TASIC3ALDH1A1GAA
SCHEMBL5401254 0.83 MAPT (0.58) MAPTUBE2TASIC3ALDH1A1GAA
SCHEMBL10759561 0.81 MAPT (0.56) MAPTUBE2TASIC3ALDH1A1GAA
SCHEMBL16698059 0.80 MAPT (1.00) MAPTUBE2TASIC3ALDH1A1GAA
SCHEMBL16698060 0.80 MAPT (1.00) MAPTUBE2TASIC3ALDH1A1GAA
SCHEMBL11088908 0.79 MAPT (0.54) MAPTUBE2TASIC3ALDH1A1GAA
SCHEMBL11469068 0.79 MAPT (0.55) MAPTUBE2TASIC3ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
EP-0006347-A1 Compositions and method for regulating soybean plant growth utilizing substituted benzazolylthioalkanoic acids MONSANTO COMPANY (US) 1980-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 MAPT 3069/4885UBE2T 1834/4885ASIC3 4557/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 MAPT 3958/4885UBE2T 2631/4885ASIC3 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.